Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of T Cells on Age-related Vascular Dysfunction
NCT04344873Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of abatacept in vascular dysfunction, sponsored by University of Utah. Primary endpoints: Change in brachial arterial diameter at 7 weeks and Change in brachial arterial flow rate at 7 weeks. Planned start Sep 2025; status: withdrawn.
02
Drugs
abatacept
03
Conditions
vascular dysfunction
Beyond the preview
Go deeper on NCT04344873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344873.